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CONFORMATIONAL REGULATION OF MEMBRANE
LOCALIZATION AND ACTIVATION OF TALIN

PALLAVI DWIVEDI

ABSTRACT
Talin is a cytosolic protein which is known to be one of the key players involved
in integrin mediated cell adhesion dependent processes, including blood coagulation,
tissue redmodeling. It connects the extracellular matrix with the actin cytoskeleton. Talin
comprises of a head domain (talin-H) and a rod domain (talin-R). Talin-H is further
subdivided in F0, F1, F2 and F3 domains. Talin-R contains 13 contiguous helical bundle
domains (R1-R13) followed by an actin binding dimerization domain (DD). The F3
domain contains a key integrin binding site that regulates integrin activation. In our
previous studies, we have shown that cytosolic talin exists in an autoinhibited state
where the integrin binding site in F3 domain

is self-masked by R9 domain. The

autoinhibited talin is randomly distributed in the cytosol but upon activation, talin is
rapidly localized to membrane and it binds and activates integrin. The main focus of the
present study was to understand the mechanism of plasma membrane localization and
activation of talin. Since talin has long been known to also bind to actin, we also
investigated the actin binding sites in talin and how they are conformationaly regulated.
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The crystal structure of autoinhibited talin F2F3-R9 complex, previously
determined in our lab, revealed a stretch of negatively charged residues on R9 which is
located on the same side as the positively charged surface on talin H. This leads to two
hypotheses: (I) Electrostatic repulsion between the negatively charged talin-R9 surface
and membrane promotes the cytosolic retention of autoinhibited talin; (II) upon
enrichment of membrane with negatively charged phosphatidylinositol-4,5-bisphosphate
(PIP2), PIP2 strongly pulls the positively charged surface on talin-H towards membrane
and simultaneously repels the negatively charged surface on R9, thus promoting the
membrane localization and activation of autoinhibited talin via a “pull-push” mechanism.
To test the hypothesis I, we made a triple mutant (H1711E, T1812E, N1815E) on the
talin-R9 (talin-3E mutant) to make it more negatively charged. Our cosedimentation
experiment demonstrates that the talin mutant has significantly reduced ability to
associate with membrane as compared to the WT talin, thus supporting the hypothesis I.
To test the hypothesis II, we made a triple mutant (D1676R, E1770K, M319A) to weaken
the talin-F3/R9 autoinhibitory interaction (talin-activation mutant). The co-sedimentation
experiment demonstrates that the talin-activation mutant had substantially increased
capacity to bind to membrane as compared to WT talin, indicating that the relief of the
autoinhibition promoted the “pulling” of talin-H to membrane and “pushing” away of
talin-R from membrane. Consistently, the talin-activation mutant had increased integrinbinding, leading to significantly enhanced talin-mediated integrin activation as compared
to WT talin.
Consistent with previous studies, we found the presence of three actin binding
sites on talin. Interestingly, full length talin has little binding to actin, suggesting that the
v

full length talin adopts a conformation that not only prevents integrin binding but also the
actin binding. Disruption of the autoinhibitory interface that masks the integrin binding
increased the talin binding to integrin but not to actin, suggesting that the two binding
events are regulated by different conformational activation mechanisms.
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CHAPTER I
INTRODUCTION

1.1

Integrins

Integrins are heterodimeric transmembrane glycoprotein receptors comprising two
subunits α and β which are noncovalently associated with each other. Integrins serve as a
mode of interaction of cells with the extracelluar matrix. These receptors play a vital role
in cell adhesion and migration. Till date 18α and 8β subunits are known in vertebrates
which form 24 distinct integrin receptors which possess different binding properties and
are differentially expressed in various tissues (Johnson et al, 2009). For instance, αııb
subunit pairs up with subunit β₃ to form a heterodimeric receptor αııbβ₃ in platelets
which recognizes Arg-Gly-Asp (RGD) peptides in extracellular matrix molecules such as
fibrinogen and vitronectin.
Both α and β subunits contain a large extracellular domain, a single membrane
spanning transmembrane domain and cytoplasmic tail (figure 1). The extracellular
domain of α subunit comprises of inserted domain or von Willebrand factor A domain
1
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(Lee at al.,1995), β propeller domain (Springer et al.,1997) and leg or stalk comprising of
thigh domain and calf1 and calf 2 domains (Xiong et al.,2001; Zhu et al.,2008).

Figure 1 Integrin αııbβ₃ : Integrins are heterodimeric receptors comprising of α and β subunits. The
extracellular domain of αııb comprises of β-propeller domain, the thigh domain , calf-1 and calf-2
domains. The extracellular portion of β₃ subunit comprises of βA domain, hybrid domain, PSI
(plexin/semaphorin/integrin) domain, four EGF domains (Epidermal growth factor-like domains)
and a β TD domain. The figure shows the ‘bent’ or inactive form of integrin and ‘extended’ or active
form of integrin which is capable of binding to it’s ligand (adapted from Ma et al., 2007)

The inserted domain contains α helices contains a dinucleotide binding or Rossmann
fold and it also contains a metal ion dependent adhesion site (MIDAS) which is important
for binding to ligand. The β propeller domain forms an interface with the β subunit. The
bent or low affinity state of integrins has been suggested to undergo a conformational
rearrangement and extension with a switch blade like motion upon inside out signaling
and binding binding to a ligand (Takagi et al., 2002; Xiong et al., 2002; Luo et al.,2007;
Xiao et al.,2004). The ‘genu’ or the key point where switchblade like rearrangement
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occurs in α subunit is formed by a calcium ion binding loop present between thigh and
calf 1 domains of α subunit.
The extracellular domain of β subunit comprises of inserted domain or βA domain,
hybrid domain, Plexin/semaphorin/integrin (PSI) domain and leg or stalk which contains
integrin epidermal growth factor like domain (IEGF) and β ankle and αβ tail domain (Shi
et al., 2005). The inserted domain of β subunit forms an interface with β propeller of α
subunit and like inserted domain of α subunit, it also contains MIDAS which binds
magnesium ion and an additional metal ion binding site known as Synergistic metal ion
binding site which binds calcium ion (Huang et al., 2000). The ‘genu’ or bent in the β
subunit has been suggested to occur between I-EGF domains 1 and 2. The structure of the
extracellular domain of αııbβ₃ in the ligand bound state and inserted domain of β subunit
of αᵥβ₃ in absence of ligand suggests that rearrangement of extracellular domain from
closed to open conformation occurs following disruption of the interface between
inserted domain of β subunit and hybrid domain. The rearrangement of residues in
MIDAS and axial displacement of α7 helix of inserted domain leads to swinging out of
hybrid domain of β subunit thereby disrupting it’s interface with inserted domain.
As revealed in the structure of integrin αııbβ₃, there is an association between
transmembrane domains of αııb GXXXG motif and β₃ subunit in bent conformation
(Xiong et al., 2001; Zhu et al., 2009). Also, the studies on cytoplasmic domains of α and
β subunits using FRET (Fluorescence Resonance Energy transfer) have suggested that in
resting state the cytoplasmic tails are close to each other and show spatial separation upon
binding of talin head domain or phorbol ester (Kim et al., 2003). The disruption of the
association of transmembrane and cytoplasmic domains of α and β subunits by making
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mutations in specific residues has been shown to activate integrins (Luo et al., 2004;
Partridge et al., 2005; Luo et al., 2005).
Integrins have been shown to work as bidirectional signalling receptors (Hynes et al.,
2002). Agonist stimulation leads to signalling response within cells and recruitment of
signaling proteins onto the integrin α and β cytoplasmic tails which in turn results in
activation of integrins. This process is known as inside-out signalling. The formation of a
large signaling complex known as focal adhesion takes place in response to binding of a
ligand to intgerins. The focal adhesion complex comprises of integrins clustered within
the plasma membrane and signaling molecules assembled onto the cytoplasmic tails of
integrins. This process is referred to as outside-in signalling (Abram et al., 2009).

1.2

Talin

Talin was initially identified as a cytoskeletal protein which localises in adhesion
plaques in ruffling membranes of fibroblasts (Burridge et al., 1983), myotendinous
junctions of skeletal muscles (Tidball et al., 1986) and in platelets (Fox et al., 1985).
Later studies identified integrins and vinculin as binding partners of talin in cells
(Burridge et al., 1984). Talin comprises of N-terminal FERM (protein 4.1, Ezrin, radixin
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and moesin) domain-like talin head domain and C-terminal rod domain (figure 2). The
head domain is further subdivided into F0, F1, F2 and F3 domains. The talin rod domain
is composed of a series of helical bundle subdomains followed by a carboxyl terminal
dimerization domain (DD) (figure 2).

Figure 2 Talin comprises of a head domain and a rod domain. The head domain is subdivided into
F0, F1, F2 and F3 subdomians. The rod domain is further subdivided into 13 helical bundle
subdomains R1 (482-655), R2 (656-786), R3 (787-911), R4 (913-1044), R5 (1045-1206), R6 (12061357), R7 (1358-1653), R8 (1461-1580), R9 (1654-1822), R10 (1823-1973), R11 (1974-2140), R12
(2141-2294), R13 (2300-2482) and DD (2494-2541) followed by carboxyl terminal dimerization
domain (DD). The F3 subdomain contains the integrin binding site (IBS 1) which is responsible for
activating integrins. F2 and F3 subdomains also contain binding sites for PIPKIγ, Layilin, Focal
adhesion kinase (FAK) and actin. The rod domain contains binding sites for actin and vinculin (VBS;
vinculin binding sites), α-Synemin and second integrin binding site (IBS2).
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The F3 subdomain has a Phosphotyrosine binding fold (PTB) which binds to
membrane proximal NPXY motif in the cytoplasmic tails of β subunit of integrin (figure
3, 4). Both F2 and F3 domains of talin have been shown to bind β₃ tail in in-vitro studies
using Surface Plasmon Resonance (SPR). Talin F3 binds integrin β₃ tail with much
higher affinity (Kd 130 ± 10nm) as compared to F2 domain (Kd 540 ± 40 nm).

Figure 3 The F3 subdomain of activated talin head domain activates integrin by binding to the
cytoplasmic tail (CT) of β subunit of integrin.

Figure 4 Talin binds to NPXY motif (shown in red) in β₃ CT of integrin αııbβ₃.
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The binding affinity of talin head domain (Kd 91 nm) is similar to that of the F3
domain. Talin has been shown to bind β₃, β₁D tails and also weakly to β₁ A tail
(Calderwood et al., 1999; Calderwood et al., 2002). In previous NMR studies, the
residues 732-750 corresponding to NPXY motif showed largest spectral changes in full
length integrin β₃ tail in presence of talin fragment encompassing F2 and F3 domains
(Vinogradova et al., 2002; Vinogradova et al., 2004; Ulmer et al., 2003).
Upon cotransfection with talin 1-1071 fragment cDNA, Chinese hamster ovary (CHO)
cells expressing integrin showed increased activation of integrin as monitored by
activation specific monoclonal antibody PAC1. On the other hand cotransfection of these
cells with talin fragment (434-1071) lacking head domain could not activate integrin.
Also, the expression of talin (1-1071) in CHO cells expressing integrin αııbβ₃ lacking Cterminal 35 amino acids of β₃ tail fails to activate integrin and cause cell spreading and
formation of focal adhesions (Calderwood et al., 2002; Calderwood et al., 1999). The
interaction of talin with integrin is also disrupted by point mutation of tyrosine (Y) in the
NPXY motif to alanine (A).
The binding of talin to membrane phosphoinositides facilitates its interaction with
integrin β cytoplasmic tails (Martel et al., 2001). The FERM domain of talin
contains a stretch of positively charged residues which aids interaction of talin with
negatively charged phosphoinosites in membrane (Kalli et al., 2013). PIPKIγ, which
locally enriches membrane with PIP2, also binds to FERM domain of talin and is
recruited to membrane by talin (Ling et al., 2002; Paolo et al., 2002). PIP2 has been
shown to activate talin (Goksoy et al., 2008). Previous studies have suggested that
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binding of PIP2 to talin sterically induces conformational change in talin and leads to its
activation (Martel et al., 2001).
Talin acts as linker between extracellular matrix and actin cytoskeleton. Disruption of
both talin alleles in mouse embryonic stem cells leads to inability to complete
gastrulation and embryonic lethality in mice (Monkley et al., 2000). The defects in talin
deficient mouse embryos have been suggested to occur due to defects in assembly of
focal adhesions and cell spreading (Priddle et al., 1998). Also, downregulation of
expression of talin in HeLa cells using antisense RNA strategy leads to decrease in
number of stress fibers and reduced rate of cell spreading (Albiges-Rizo et al., 1995).
Fusion proteins spanning the residues 102-497, 951-1327 and 2269-2541 of talin have
been shown to bind F-actin in in vitro cosedimentation assay (Hemmings et al., 1996).
These studies suggest the presence of atleast three distinct actin binding sites on talin. F2
and F3 subdomains of talin head domain have been shown to colocalize with actin stress
fibers in COS cells and cosediment with F-actin in invitro studies (Lee et al., 2004).
These findings suggest that the FERM domain of talin head contains the actin binding
site and both F2 and F3 subdomains of actin contribute to binding to actin. The
interaction of talin with actin has been shown to be affected by change in pH and ionic
strength and temperature (Schmidt et al., 1999). Also, using high resolution electron
microscopy the binding site of talin FERM domain has been mapped to subdomain 4 of
an actin monomer (Gingras et al., 2008).
The structure of COOH-terminal actin binding domain shows resemblance to HIP1R
THATCH (talin/ HIP1R/ Sla2p actin tethering C-terminal homology) core domain or
I/LWEQ motif (Brett et al., 2006; Gingras et al.,2008; McCann et al., 1997). The core of
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this domain is formed by five helix bundle spanning the residues 2300-2482. The bundle
is linked to helix 6 which forms an antiparallel dimer. The dimerisation helix is required
for binding of talin to F-actin. The helix 1 which lies on the opposite side of the five helix
bundle negatively regulates binding to F-actin. The N terminal and C terminal actin
binding sites of talin have been suggested to exhibit different characteristics (Hemmings
et al., 1996). Upon microinjection into chicken embryo fibroblasts talin GST fusion
protein spanning residues 102-497 and 1646-2541 caused disruption of actin stress fibers.
The fusion protein containing the C terminal actin binding site spanning residues 16462541 could not disrupt actin stress fibers (Bolton et al., 1997).

1.3

Binding Partners of Talin

Talin contains an integrin binding site on FERM domain (figure 2) as well as on the
rod domain (Calderwood et al., 2002; Moes et al., 2007). The integrin binding site on the
head domain of talin is responsible for activating integrin. The head domain also binds to
a splice variant of phosphatidylinositol-4-phosphate 5 kinase (PIPKIγ90) (Paolo et al.,
2002) and membrane phospholipids (Martel et al., 2001; Kalli et al., 2013). Talin has
been shown to contain three vinculin binding sites VBS1 (498-636), VBS2 (727-965) and
VBS3 (1943-2157) in the rod domain (Bass et al., 2002). The crystal structure of talin
482-789 has been determined. A five helix bundle formed by residues 482-655 forms a
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hydrophobic interface with four helix bundle formed by residues 656-789. The
hydrophobic residues L608, A612, L615, V619 and L623 form vinculin binding site in
talin rod domain. Mutations that disrupt the hydrophobic core have been shown to expose
vinculin binding site in talin. These studies suggest that talin 482-655 requires activation
in order to bind vinculin.
A 48 amino acid sequence spanning the residues 965-1012 in the carboxyl domain of
Focal adhesion kinase (FAK) has been shown to bind talin in NIH3T3 cells. The binding
site of FAK on talin comprises of residues 225-357 within talin’s FERM domain (Chen et
al., 1995; Borowsky et al., 1998). The binding of cytoplasmic domain of integrin to talin
has been suggested to lead to the activation of FAK and tyrosine phosphorylation. Layilin
has also been identified as a binding partner of talin in yeast two hybrid screen. It has
been named Layilin due to the sequence LAYILI in it’s transmembrane domain. Layilin
has a 130 amino acid domain which is homologous to C-type lectin carbohydrate
recognition domain. The amino acids 280-435 constitute the binding site for Layilin on
Talin (Borowsky et al., 1998). Another binding partner of talin, α Synemin is a member
of the intermediate filament protein family. Synemin colocalizes with talin in mammalian
muscle cells at sites of focal adhesion. α Synemin contains a 312 amino acid insert (SNT
III) which binds to rod domain of talin (Sun et al., 2008). Talin has been shown to bind
actin (Hemmings et al., 1996; Lee et al., 2004).
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1.4

Aim of the Project

The head domain of talin (Talin-H) activates integrin by separating a key cytoplasmic
clasp of integrin α and β subunits (Kim et al., 2003). The stretches of positively charged
surfaces on talin-H have been suggested to facilitate interaction of talin-H with integrin β
cytoplasmic tail by promoting binding of talin to plasma membrane (Kalli et al., 2013).
We found that rod domain of talin specifically talin-R9 sterically blocks the integrin
membrane proximal β cytoplasmic tail site on talin-F3 (Goksoy et al,2008). This finding
explains how conformational regulation of talin in turn regulates talin mediated integrin
activation. However, the following questions still remain unaddressed:

1. How is talin retained in the cytoplasm? Talin has long been known to be
randomly distributed in cytosol in resting cells. However, the mechanism which
determines the cytosolic retention of talin so that it is incapable of binding to
integrin is unknown.
2. How is talin localized to the membrane and activated to bind integrin? PIPKIγ
kinase, recruited by talin to the membrane enriches membrane with PIP2. PIP2
has been shown to promote talin mediated integrin activation (Goksoy et al.,
2008). However, how does PIP2 help in localization of talin to the membrane and
it’s activation is not well understood (Song et al., 2012).
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3. How is the interaction of talin with actin regulated? Talin has long been known to
act as a linker between extracellular matrix and actin cytoskeleton at sites of cell
adhesion to substrate. Previous studies have indicated the presence of multiple
sites on talin. However, the mechanism which regulates the interaction of talin
with actin and which of the previously reported actin binding sites in
autoinhibited talin are available to bind to actin in resting cells remains unclear.

Our crystal structure of Talin F2F3/R9 autoinhibitory complex (figure 4; Song et al.,
2012) revealed a stretch of negatively charged residues on rod domain of talin which is
located on the same side as the stretch of positively charged residues on talin F2F3.
Based on this finding I propose the following studies to address the above questions.

1. Test the hypothesis that electrostatic repulsion between the negatively charged
talin-R9 surface and membrane promotes the cytosolic retention of autoinhibited
talin. We will use lipid cosedimentation assay to compare the binding abilities of
purified talin fragments F2F3, F2DD , FL talin and FL mutant (H1711E, T1812E,
N1815E), R1-R9, R9 (figure 2) to MLVs (multilamellar vesicles) enriched with
lipids found on the inner surface of plasma membrane such as PIP2
(Phosphatidylinositol-4,5-bisphosphate), POPS (1-palmitoyl-2-oleoyl-sn-glycero3-[phosphor-L-serine])

and

POPC

(1-palmitoyl-2-oleoyl-sn-glycero-3-

phosphocholine). To determine whether localization of FL talin and FL talin
mutant (T1767L, E1770K, M319A) to membrane also affects the ability of
these proteins to activate integrin, we will use integrin activation assay in CHO
cells. The integrin activation assay is based on analyzing the binding of the

13
monoclonal antibody PAC1 which specifically binds to activated integrins using
FACS (Fluorescence activated cell sorting).
2. Test the hypothesis that upon enrichment of membrane with negatively charged
PIP2, PIP2 strongly pulls the positively charged surface on talin-H towards
membrane and simultaneously repels the negatively charged surface on R9, thus
promoting the membrane localization and activation of autoinhibited talin via a
”pull-push” mechanism. We will use lipid cosedimentation assay to compare the
binding ability of purified talin fragments F2R9 and F2R9 mutant (D1676R,
E1770K, M319A) to MLVs enriched in varying concentrations of PIP2 (5-20%).
The assay will help us determine how the weakening of autoinhibitory F2F3/R9
interface in talin F2R9 (D1676R, E1770K, M319A) affects it’s ability to bind to
MLVs as compared to wild type F2R9.
3. Weakening of the Talin F2F3/Talin R9 autoinhibitory interface leads to talin
mediated integrin activation. We will use NMR to determine the chemical shift
perturbation of labeled integrin β₃ cytoplasmic tail in presence of F2F3, F2R9
wild type , F2R9 mutant (D1676R, M319A, E1770K) and FL talin. We will also
determine the integrin αııbβ₃ activation caused by talin FL and talin FL mutant
(T1767L, E177K, M319A) in CHO cells. The talin FL mutant (T1767L, E1770K,
M319A) bears three mutations in it’s F2F3/R9 autoinhibitory interface which help
to weaken the autoinhbitory interaction in talin.
4. Investigate the reported actin binding sites in talin and examine how they may
also be autoinhibited in full length talin. We will use purified talin fragments
F2F3, R1-R9, R13, R13-DD, F2R9, F2R10, F2R12, F2DD, FL and FL mutant
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(T1767L, E1770K, M319A) in the F-actin cosedimentation assay to determine the
actin binding sites in talin and to compare the ability of different talin fragments
to bind to F-actin.

CHAPTER II
MATERIALS AND METHODS

2.1

Protein Preparation and Purification

Talin fragments F2R9 (206-1848), F2R10 (206-1973), F2R12 (206-2294), F2DD (2062541), R1R9 (486-1848) and F0DD (1-2541) (figure 2) were subcloned into the parallel
His-1 vector pET 28t containing a N-terminal His- tag. The talin fragments were
expressed in E.coli strain BL21 (DE3) and the cells were lysed using 10 mg/ml lysozyme.
All the talin fragments were purified on nickel affinity column as described previously
(Begona et al., 2003). Briefly, the proteins were eluted with 250mM imidazole in the
elution buffer (20mM Tris-HCl, 500mM NaCl, 1mM DTT, pH 8.0). The eluted proteins
were dialyzed against the dialysis buffer (20mM Tris-HCl, 150mM NaCl, 1mM DTT,
pH7.4). The proteins were further purified by size exclusion chromatography. Superdex200 (Amersham Biosciences) was used for F2R9, F2R10 and F2R12 and Superose-6 was
used for other talin fragments. Talin F2F3 (206-405) and R9 (1654-1848) were prepared
as described previously (Goksoy et al., 2008). Triple mutation of talin F2R9 (D1676R,
15
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E1770K, M319A) FL (H1711E, T1812E, N1815E) and FL(T1767L, M319A, E1770K)
were made using QuickChange Site-Directed mutagenesis (Stratagene) and prepared in
the same way as wild type.

2.2.

Lipid Vesicle Preparation and Lipid Cosedimentation Assay

The phospholipids such as POPC, POPS, PIP2 (figure 8) used to make multilamellar
vesicles (MLV) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). The
lipids were dissolved together in chloroform in a vial. The chloroform was removed
under a stream of nitrogen followed by lyophilization. The lipids formed a film inside the
vials. The lipid film was then hydrated in the phosphate buffer (50 mM
Na2HPO4/NaH2PO4, 50 mM NaCl, 2mM NaN3, and pH 6.8) followed by homogenization
with repeated freeze thaw cycles to form MLVs. The MLVs were mixed with purified
talin fragments F2F3 (206-405), F2R9 (206-1848), FL (1-2541), F2DD (206-2541), FL
mutant (H1711E, T1812E, N1815E) and F2R9 mutant (D1676R, E1770K, M319A) in
separate centrifuge tubes in molar ratio of 1:20 on a shaker at room temperature for 20
minutes followed by centrifugation at 14000 rpm for 30 minutes. The lipids formed a
pellet at the bottom of the centrifuge tubes. The pellets were resuspended in 40 μl 1X
SDS and 10μl of 4X SDS was added to supernatant from all the samples.
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2.3

Actin Cosedimentation Assay

Actin purified from rabbit skeletal muscle was purchased from Cytoskeleton. Actin
and purified talin fragments F2F3 (206-405), F2R9 (206-1848), F2R10 (206-1973),
F2R12 (206-2294), F2DD (206-2541), FL (1-2541), R13-DD (2300-2541), R13 (23002482) and FL mutant (M319A, E1770K, T1767L) were mixed in separate centrifuge
tubes in a molar ratio of 1:2 in a total volume of 50 μl of F-actin buffer (10mM tris-Hcl
pH 8.0, 0.2mM ATP, 0.2 mM DTT, 0.2mM CaCl2 and 100 mM NaCl). The samples
were then incubated at room temperature for 20 minutes and centrifuged at 63000 rpm at
24 C for 90 minutes. The supernatant was removed in separate tubes and pellets were
washed carefully with F-actin buffer. The pellets were resuspended in 60 μl of 1X SDS.
10μl of 4X SDS was added to supernatant from all the samples. Equal volumes of pellet
and supernatant were loaded onto 4-20% Tris-glycine gels and protein content of the
samples was resolved by SDS-PAGE. The gels were stained by Coomassie blue and the
intensity of bands on gel was analysed using Image J.

2.4

NMR Spectroscopy

The heteronuclear NMR experiments were performed at 25 °C on Bruker Avance 600
MHz spectrometers equipped with cryogenic triple resonance probes and shielded zgradient units as described previously (Song et al, 2012). The HSQC experiments to
determine the interaction between talin and integrin β3 cytoplasmic tail (CT) were
performed with ¹5N-labeled β3 CT and unlabeled talin F2F3, F2R9, F2R9 mutant
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(D1676R, E1770K, M319A) and

full length in phosphate buffer (50 mM

Na2HPO4/NaH2PO4, 50 mM NaCl, 2mM NaN3, and pH 6.8). The weighted chemical
shift changes of amide proton and nitrogen were calculated using the equation:
Δδobs[HN,N]=([ΔδHNWHN]2+[ΔδNWN]2)1/2, where WHN (1.0) and WN (0.154) are weighting
factors based on the gyromagnetic ratios of 1H and
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N. NMR data was processed and

analyzed using nmrPipe (Delaglio et al., 1995), PIPP (Garrett et al., 1991) and Sparky
(Lee et al., 2009).

2.5

Integrin αııbβ3 Activation Assay

Chinese hamster ovary (CHO) cells stably expressing integrin αııbβ3 were transfected
with EGFP vector alone, full length talin wild type and full length talin mutant (T1767L,
M319A, E1770K). The effects of full length talin and and talin mutant on integrin were
evaluated with PAC1, a monoclonal antibody which specifically recognizes active αııbβ3
as described previously (Ma et al., 2008; Goksoy et al., 2008). Briefly, 24 hours after
transfection, the cells were harvested and stained with PAC1 followed by Alexa Fluor
633 goat anti-mouse IgM conjugate. The cells were then washed, fixed and analyzed by
Flow Cytometry, gating only on the EGFP positive cells. Mean Fluorescence intensities
(MFI) of PAC1 bound to EGFP-talin or EGFP-talin mutant expressing cells were
compared with MFI of PAC1 bound to the CHO cells expressing EGFP vector alone.
Three independent experiments were performed, and the T-student test was used for
statistical analysis.

CHAPTER III
RESULTS AND DISCUSSION

3.1 Results

3.1.1 PIP2 regulates membrane localization and activation of talin

Talin F2F3 contains stretch of positively charged residues which enables talin to bind
membrane and mediate integrin activation by binding to cytoplasmic tails of integrin’s β
subunit (Kalli et al., 2013; Song et al., 2012). Also, Talin recruits PIPKIγ kinase which in
turn enriches membrane with lipid phosphatidylinositol-4, 5-bisphosphate (PIP2) (Paolo
et al., 2002). PIP2 helps to activate autoinhibited talin (Goksoy et al., 2008). The
structure of talin F3-R9 autoinhibitory complex (Figure 5, 6), showed a stretch of
negatively charged residues on talin R9 which is located on the same side as stretch of
positively charged residues on F2F3 (Song et al., 2012).
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Figure 5 Crystal structure of talin-F2F3-R9 autoinhibitory complex. The talin head subdomains F2
and F2 are shown in green and talin rod subdomain R9 is shown in blue (adapted from Song et al .,
2012).

Figure 6 The positive charge enriched region is shown in blue and negative charge enriched region is
shown in red. A stretch of positive charged residues on talin F2F3 is located on the same side as a
stretch of negatively charged residues on talin R9 (adapted from Song et al., 2012)

We found that binding of free F2F3 to R9 was disrupted by addition of multilamellar
vesicles (MLV) containing PIP2 to the F2F3-R9 complex using NMR based competition
experiments. Also, PIP2 was shown to bind F2F3 bivalently.
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In the present study, we used MLVs (multilamellar vesicles) in lipid cosedimentation
assay to simulate the plasma membrane in vitro. We used the lipids PIP2, POPS and
POPC to prepare the MLVS, all of which are found on the inner surface of plasma
membrane (Figure 7-9).

Figure 7 Chemical structure of PIP2(Phosphatidylinositol-4,5-bisphosphate)

Figure 8 Chemical structure of POPS (palmitoyl-2-oleoyl-sn-glycero-3-[phosphor-L-serine])

Figure 9 Chemical structure of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)

For the lipid cosedimentation assay, we prepared MLVs containing only POPC as well
as MLVs of mixed lipids (20% POPS; 80% POPC and 20% PIP2; 20% POPS, 60%
POPC). To study the effect of negatively charged surface on rod domain of talin on the
membrane binding ability of talin, we mixed together purified talin fragments F2F3,

22
F2DD, R1-R9, R9 and FL talin in separate centrifuge tubes along with MLVs. Upon
centrifugation of all the samples at 13000 rpm at room temperature for 30 minutes, the
MLVs formed a pellet at the bottom of the centrifuge tubes. We resolved the amount of
protein present in the pellet and supernatant of all the samples by SDS-PAGE.
We found that F2F3 showed strong binding to membrane with most of it pelleting
down along with the MLVs at 20% PIP2 (figure 10, 14). MLVs containing 20% PIP2
showed stronger binding to talin F2F3 as compared to MLVs containing 20% POPS and
POPC due to the presence of higher negative charge on the head group (inositol-1,4,5trisphosphate) of PIP2.
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206-405 Talin

206-405 Talin + POPC

206-405 Talin + POPC

206-405 Talin + 20% POPS

206-405 Talin + 20% PIP2

206-405 Talin + 20% PIP2
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20

206-405 Talin + 20% POPS

Figure 10 Lipid cosedimentation assay: In presence of MLVs enriched in 20% PIP2 whole of the
talin F2F3 was found bound to MLVs in the pellet. Talin F2F3 shows significantly increased binding
to MLVs containing 20 % PIP2 as compared to MLVs containing 20% POPS and POPC due to
higher negative charge on head group of PIP2 as compared to POPS and POPC.
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F2DD and FL talin showed lesser binding to membrane with most of the protein
remaining in the supernatant at 20% PIP2 (Figure 11,13,14). R9 and R1-R9 showed no
binding to membrane (Figure 12).
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FL Talin + 20% POPS
FL Talin + POPC
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206-2541 Talin + 20% PIP2

P S P S P S

206-2541 Talin + 20% PIP2
206-2541 Talin + 20% POPS
206-2541 Talin + 20% POPS
206-2541 Talin + POPC

P S P S P S P S
250

Figure 11 Lipid cosedimentation assay : Talin F2DD (206-2541) and FL(1-2541) did not pellet down
in absence of MLVs. In presence of MLVs containing 20 % PIP2, talin F2DD and FL showed little
binding to MLVs.
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1654-1848 + 20% PIP2
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% of Total in pellet at 20
% PIP2

Figure 12 Lipid cosedimentation assay: Talin R1-R9 (486-1848) and R9 (1654-1848) showed no
binding to MLVs containing 20% PIP2.
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Figure 13 Image J was used to quantify the amount of protein in Figure 10, 11 and 12. The amount of
talin is expressed as percent of total protein found in pellet. Bar graph represents mean ±S.E. (n≥3).
N.S., not significant, p>0.05; *, p=0.01-0.05; **, p=0.001-0.01. Talin F2F3 (206-405) showed
significantly higher binding to MLVs containing 20 % PIP2 as compared to F2DD (206-2541) and
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FL talin (1-2541). Talin R1-R9 (486-1848) and R9 (1654-1848) showed no binding to MLVs
containing 20% PIP2.

***

% of total in Pellet

120
100

POPC
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*
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40
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0

FL Talin

206-2541

206-405

Figure 14 Image J was used to quantify the amount of protein in figure 10, 11. The amount of talin is
expressed as percent of total protein found in pellet. Bar graph represents mean ±S.E. (n≥3). N.S.,
not significant, p>0.05; *, p=0.01-0.05; **, p=0.001-0.01;***, p<0.001. Talin F2F3 (206-405) and FL
talin showed significantly higher binding to MLVs containing 20 % PIP2 as compared to MLVs
containing 20% POPS.

An increase in the concentration of NaCl in the buffer (20 mM Tris-HCl, 300mM
NaCl, 1mM DTT, pH 8.0) used for the lipid cosedimentation assay resulted in
impairment of electrostatic interaction between MLVs containing 20% PIP2 and the rod
domain of talin and most of the talin F2R9 was found bound to the MLVs in pellet
(figure 15).
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S

P
150 KDa

206-1848 Talin + 20% PIP2

206-1848 Talin + 20% PIP2

Figure 15 Lipid cosedimentation assay: Most of Talin F2R9 (206-1848) protein pelleted
down along with MLVs containing 20% PIP2 due to an increase in the concentration of
NaCl in buffer (20mM Tris-HCl, 300mM NaCL, 1mM DTT, pH 8.0) used for the assay.
The higher concentration of NaCl impaired the electrostatic interaction between the
MLVs and negatively charged R9.

We prepared MLVs enriched in varying concentrations of PIP2 and POPC and kept
the concentration of POPS (20%) constant. We used these MLVs enriched with 1% PIP2,
5% PIP2, 10% PIP2, 20% PIP2 and 50% PIP2 to find out whether gradual increase in
concentration of PIP2 would increase the amount of talin bound to membrane. As shown
in Figure 16, 17, talin F2F3 showed gradual increase in amount of protein cosedimenting
with MLVs in pellet with increase in concentration of PIP2 in MLVs and whole of F2F3
was found in pellet at 20% PIP2.
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Figure 16 Lipid cosedimentation assay: The amount of Talin F2F3 (206-405) pelleting down with
MLVs gradually increased with increase in the percentage of PIP2 (1-20%) in MLVs.
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Figure 17 Image J was used to quantify the amount of protein in Figure 16. The amount of talin is
expressed as percent of total protein found in pellet. Bar graph represents mean ±S.E. (n≥3). N.S.,
not significant, p>0.05; ***, p<0.001. Talin F2F3 (206-405) shows strong binding to MLVs enriched
in 20% PIP2.
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At 50% PIP2 more than half of the total FL wild type talin was found in pellet (Figure
18, 19). In order to further increase the repulsion between R9 and membrane we mutated
three residues in the R9 domain to make talin 3E mutant (H1711E, T1812E, N1815E).
As shown in figure 18, 19, at 20% PIP2 almost whole of the 3E mutant was in the
supernatant and at 50% PIP2 the amount of 3E mutant which

pelleted down was

significantly less as compared to wild type FL talin. These findings suggest that the
electrostatic repulsion between the negatively charged surface on R9 and membrane
prevents membrane localization of autoinhibited talin.
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150 KDa

Figure 18 Lipid cosedimentation assay: The amount of wild type FL talin which pellets down with
MLVs gradually increases with increase in percentage of PIP2 in MLVs. At 50% PIP2
approximately 60% of total FL talin goes to pellet along with MLVs. FL 3E mutant (H1711E,
T1812E, N1815E) shows significantly reduced binding to MLVs containing 20% PIP2 and 50% PIP2
as compared to wild type FL talin. The increased repulsion between the rod domain of talin 3E
mutant and MLVs containing 20% PIP2 and 50% PIP2 results in reduced binding of FL 3E mutant
to MLVs.
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Figure 19 Image J was used to quantify the amount of protein in figure 18. The amount of talin is
expressed as percent of total protein found in pellet. Bar graph represents mean ±S.E. (n≥3). N.S.,
not significant, **, p=0.001-0.01. Talin 3E mutant (H1711E, T1812E, N1815E) showed significantly
reduced binding to MLVs containing 20% PIP2 and 50% PIP2 as compared to wild type FL talin.

Next we wanted to test the hypothesis that enrichment of membrane with negatively
charged phospholipid PIP2 strongly attracts positively charged surface on talin-H and
simultaneously repels negatively charged talin R9 and therefore promotes membrane
localization and activation of autoinhibited talin. Based on the crystal structure of
F2F3/R9 autoinhibitory complex (figure 20-21), we made a talin F2R9 (206-1848) triple
mutant (D1676 R, E1770K, M319A) to weaken the autoinhibitory interaction of talin
F2F3 and R9.
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Figure 20 Close-up view of talin F2F3/ R9 interface shows the amino acid side chains of residues
(K318-K324) (adapted from Song et al., 2012).

Figure 21 Close-up view of talin F2F3/ R9 interface shows the amino acid side chains of residues
(D369-Y377) (adapted from Song et al., 2012).

The F2R9 triple mutant showed an increased binding to membrane even at 5% PIP2 as
compared to wild type F2R9 (Figure 22, 23). At 50% PIP2, the F2R9 active mutant
completely cosedimented with MLVs in pellet.
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Figure 22
Lipid cosedimentation assay: Approximately 35% of total Talin F2R9 (206-1848)
wild type pellets down with MLVs containing 20% PIP2 and 50% PIP2 due to pulling of positively
charged F2F3 towards MLVs and pushing away of negatively charged R9 from MLVs. Weakening of
the autoinhibitory interface in F2R9 (206-1848) mutant (D1676R, E1770K, M319A) causes
significantly increased binding of the F2R9 mutant to MLVs lower percentage (5%) of PIP2 as well
as at higher (50%) of PIP2 as compared to wild type F2R9.
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Figure 23 Image J was used to quantify the amount of protein in figure 22. The amount of talin is
expressed as percent of total protein found in pellet. Bar graph represents mean ±S.E. (n≥3). N.S.,
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not significant, p>0.05; **, p=0.001-0.01;***, p<0.001. Due to weakening of the F2F3/R9
autoinhibitory interface, talin F2R9 (206-1848) mutant (D1676R, E1770K, M319A) showed
significantly increased binding to MLVs containing 20%POPS, 5%PIP2, 20% PIP2 and 50% PIP2
as compared to wild type F2R9.

The above findings suggest that electrostatic repulsion between negatively charged
membrane (MLVs) and the rod domain of talin significantly reduced the amount of FL
and F2DD talin which bound to MLVs enriched in 20% PIP2. On the other hand whole
of talin F2F3 could bind to the pellet containing MLVs enriched in 20% PIP2 due to the
absence of negatively charged talin rod domain. An increase in the percentage of PIP2 in
MLVs to 50% led to strong pulling of the positively charged talin F2F3 towards
membrane and pushing of R9 away from the membrane which in turn resulted in
increased amount of FL talin pelleting down along with MLVs. Due to further increase
in repulsion between the rod domain of FL 3E mutant (H1711E, T1812E, N1815E) and
MLVs, the amount of FL 3E mutant which bound to MLVs at 20% PIP2 and 50% PIP2
was significantly reduced as compared to wild type FL talin. The weakening of
talinF3/R9 autoinhibitory interaction in F2R9 mutant (D1676R, E1770K, E1770K)
promoted the pulling of F2F3 towards membrane and pushing away of R9 away from the
the membrane. Therefore, F2R9 mutant (D1676R, E1770K, E1770K) showed
significantly enhanced binding to membrane as compared to wild type F2R9. This
finding supports the hypothesis that enrichment of membrane with PIP2 promotes
membrane localization and activation of talin via a “pull-push” mechanism.
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3.1.2 Disruption of F2F3-R9 autoinhibitory interface of talin leads to integrin
activation

Extensive cell based, genetic and biochemical studies have shown that talin is required
for integrin activation. In our previous studies, we have shown that talin R9 self-masks
the integrin binding site in F3 domain and competes with integrin β-MP-CT for binding
to it (Goksoy et al., 2008). This implies that disruption of Talin F2F3-R9 interface is
required for activation of cytosolic talin in cells. We used 2D

1

H -15N HSQC

(heteronuclear single quantum correlation) to study the interaction between

15

N-labeled

integrin β₃ cytoplasmic tail and unlabeled Talin F2F3, wild type Talin F2R9 and F2R9
triple mutant (D1676R, E1770K, M319A) and FL talin (Figure 24). All the proteins were
well folded as determined by its chemical shift dispersion pattern. We found that F2R9
wild type had little effect on the HSQC spectrum of integrin β₃ CT as compared to talin
F2F3 which caused chemical shift perturbation in the membrane proximal region of β₃
CT. F2R9 wt showed some perturbation particularly in the membrane distal region of
integrin. On the other hand the triple mutant of F2R9 showed enhanced binding to β₃ CT
as compared to F2R9 wild type and caused perturbation in the membrane proximal region
of integrin-β₃ CT.
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Figure 24 Chemical shift perturbation profiles for integrin β₃ CT upon binding to Talin F2F3, F2R9,
F2R9 (M319A E1770K T1767L) and FL talin (Tln). The residues in membrane proximal region of
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integrin β₃ CT were significantly perturbed by Talin F2F3 and F2R9 mutant (T1767L M319A
E1770K). F2R9 caused some chemical shift changes in membrane distal region. (Residues whose
signals were diminished due to severe line- broadening are indicated by *)

We transfected Chinese hamster ovary (CHO) cell line stably expressing integrin
αІІbβ₃ with FL talin wild type and FL talin triple mutant (M319A, E1770K, T1767L)
EGFP constructs. We used a mAb (PAC1) which specifically recognizes activated αІІbβ₃
integrin to determine the activation state of αІІbβ₃ in these cells by FACS. The data in
figure 25 from three independent experiments shows that the FL talin triple mutant could
bind and activate αІІbβ₃ integrin significantly better than FL talin wild type in CHO cells.
These results are consistent with those obtained from HSQC experiments (figure 24).
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Figure 25 Comparison of the activation of integrin αııbβ₃ by Full length (FL) wild type talin and FL
talin mutant (T1767L M319A E1770K). As described previously (Ma et al., 2008), the effects of FL
wild type talin and talin mutant (T1767L M319A E1770K) on integrin activation were analyzed using
CHO cells stably expressing integrin αııbβ₃ and an activation specific mAb (PAC 1). The weakening
of the F2F3/R9 autoinhibitory interface in FL talin mutant (T1767L M319A E1770K) significantly
enhanced it’s ability to activate integrin αııbβ₃ in CHO cells as compared to wild type FL talin. The
data are representative of three independent experiments (means±SE). (n≥3) p>0.05; * indicates
p<0.05.
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3.1.3 FL Talin is Conformationaly Restricted to Bind Actin

Talin is known to act as a linker between integrins and actin cytoskeleton. Talin has
been suggested to contain atleast three actin binding sites. It has been shown to be able to
bind both G-actin and F-actin in cosedimentation assay (Muguruma et al., 1990). In the
presence of MgCl2 and KCl, Talin stimulates the rate of polymerization of G-actin.
However, Talin has not been shown to affect final viscosity of F-actin and was therefore
suggested to lack the ability to cross-link or bundle actin filaments.
In the present study we used talin F2F3 (206-405), F2R9 (206-1848), F2R10 (2061973), F2R12 (206-2294), F2DD (206-2541), FL, R13DD (2300-2541), R13 (2300-2482)
and R9 (1654-1848) to investigate the reported actin binding sites in talin. The
monomeric form of actin (Globular actin) and purified talin fragments were mixed
together in separate centrifuge tubes in a molar ratio of 1:2 in F-actin buffer (10mM trisHcl pH 8.0, 0.2mM ATP, 0.2 mM DTT, 0.2mM CaCl2 and 100 mM NaCl) which
allowed G-actin to polymerize in to F-actin. The samples were then centrifuged at 63000
rpm at 24°C to separate F-actin from G-actin by differential sedimentation. The F-actin
formed a pellet at the bottom of the centrifuge tubes.
We found that talin fragments F2F3, R1-R9 and R13-DD cosedimented with F-actin
in pellet (Figure 26). This finding indicates the presence of an actin binding site on talin
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F2F3, R1-R9 as well as R13-DD. Consistent with previous studies, Talin R13 (23002482) showed no binding to F-actin which indicates that DD (2494-2541)
contributes to the F- actin binding site on R13-DD (Gingras et al., 2008). Talin F2R9,
F2R10 and F2R12 showed significantly enhanced binding to F-actin as compared to
F2F3, R1-R9, FL, R13-DD and F2DD (figure 26, 27). This finding suggests that FL talin
is conformationaly restricted to bind to F-actin.
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Figure 26 F-actin cosedimentation assay: F-actin (43 KDa) pelleted down at the bottom of the tubes
following centrifugation at 63000 rpm at 24°C for 90 minutes. Talin F2F3, Talin R1-R9 (486-1848)
and R13-DD (2300-2541) showed binding to F-actin in pellet which indicates the presence of an Factin binding site on these talin fragments. Talin F2R9 (206-1848), F2R10 (206-1973) and F2R12
(206-2294) showed significantly enhanced binding to F-actin in pellet as compared to Talin F2F3 and
R1-R9 which indicates the presence of an additional F-actin-binding site on the rod domain of talin.
However, Talin F2DD and FL showed significantly reduced binding to F-actin as compared to F2R9,
F2R10 and F2R12 which suggests that FL talin and F2DD are conformationaly restricted to bind to
F-actin. R13 (2300-2482) showed no binding to F-actin suggesting that DD (2494-2541) contributes to
the F-actin binding site on R13-DD (2300-2541)
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Figure 27 Image J was used to quantify the amount of protein in figure 26 and 28. The amount of
talin is expressed as percent of total protein found in pellet. Bar graph represents mean ±S.E. (n≥3; *,
p=0.01-0.05. Talin contains an actin binding site on F2F3 (206-405), R1-R9 (486-1848) and R13-DD
(2300-2541). Talin F2R9 (206-1848), F2R10 (206-1973) and F2R12 (206-2294) showed significantly
enhanced binding to F-actin as compared to talin F2F3, R1-R9, R13-DD, F2DD and FL talin. Talin
FL and FL mutant (M319A, E1770K, T1767L) showed little binding to F-actin indicating that both
the proteins are conformationaly restricted to bind to F-actin. Thus weakening of autoinhibitory
F2F3/R9 interaction could not improve FL talin mutant’s ability to bind to F-actin. R9 (1654-1848)
and R13 (2300-2482) showed no binding to F-actin.

We compared the ability of FL active mutant (M319A, E1770K, T1767L) to bind to
F-actin with that of wild type FL talin (figure 27, 28). The FL active mutant also showed
little binding to F-actin similar to wild type FL talin. Thus weakening of the F3/R9
autoinbitory interaction in FL active mutant could not improve it’s ability to bind to Factin. The purified talin fragments dissolved in F-actin buffer did not pellet down at the
bottom of the centrifuge tubes in absence of F-actin (figure 29).
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Figure 28 F-actin cosedimentation assay: FL talin and FL talin active mutant (M319A,
E1770K, T1767L) proteins dissolved in F-actin buffer did not pellet down in absence of with
F-actin (43 KDa). In presence of F-actin, both FL talin and FL talin active mutant (M319A,
E1770K, T1767L) showed little binding to F-actin. Thus weakening of F2F3/ R9
autoinhibitory interface in FL talin active mutant did not improve it’s ability to bind to Factin.

40

P S

P S PS P S

P S

FL talin

P S

206-405 talin
206-405 talin
2300-2541 talin
2300-2541 talin
206-2294 talin
206-2294 talin

S

206-1848 talin

P

P S

250 KDa

486-4848 talin
486-1848 talin

FL talin

206-1848 talin
206-1973 talin

206-1973 talin

206-2541 talin
206-2541 talin

Figure 29: The purified talin fragments F2F3 (206-405), F2R9 (206-1848), F2R10 (206-1973), F2R12
(206-2294), F2DD (206-2541), FL (1-2541), R1-R9 (486-1848), R13DD (2300-2541) and FL talin were
dissolved in F-actin buffer. The purified talin fragments did not pellet down following centrifugation
at 63000 rpm at 24°C for 90 minutes in absence of F-actin.

The above findings show that FL talin contains an actin binding site on F2F3, R1-R9
and R13-DD. An additive effect of the actin binding sites on F2F3 and R1-R9 could lead
to the enhanced binding of talin F2R9, F2R10 and F2R12 to F-actin. However,
significantly reduced binding of FL talin to F-actin as compared to F2R9, F2R10 and
F2R12 suggests that FL talin is conformationaly restricted to bind to F-actin. The little
binding of FL talin to F-actin could be due to the masking of any of the actin binding
sites in FL talin by R13-DD. The FL talin active mutant (M319A, E1770K, T1767L)
which showed enhanced binding to integrin did not show enhanced binding to F-actin.
This finding suggests that the two binding events are regulated by different
conformational activation mechanisms.
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3.2 Discussion

Integrin mediated cell adhesion and their ability to couple extracellular matrix to actin
cytoskeleton is vital to physiological and pathological processes such as

platelet

adhesion, leukocyte transmigration, tumor vascularization and metastasis (Hynes et al.,
2002; Brooks et al., 1994; Berlin et al.,1995). Talin is an adaptor protein which plays an
important role in the function of integrins by regulating activation of integrins and linking
integrins to actin (Luo et al., 2007; Qin J. et al., 2004). The integrin binding site in Talin
F2F3 domain is self-masked by R9 (Figure 2,5) such that talin is autoinhibited to bind
integrin β cytoplasmic tail (Goksoy et al., 2008; Song et al.; 2012).
Talin is randomly distributed in cytoplasm in inactivated platelets and fibroblasts.
Upon stimulation of these cells by an agonist talin has been shown to be localised to
membrane (Beckerle et al., 1989; Banno et al., 2012). PIP2 has been shown to activate
talin (Goksoy et al., 2008). The results from our lipid co-sedimentation assay show that
talin F2F3 binds MLVs containing 20% PIP2 strongly as compared to talin FL and
F2DD (Figure 10-14). The structure of F3-R9 autoinhibitory complex revealed a stretch
of negatively charged residues on R9 which is located on the same side as the stretch of
positively charged residues on F2F3 (figure 6; Song et al.,2012). In lipid cosedimentation
assays, FL wild type talin showed enhanced binding to MLVs enriched with higher
concentration of PIP2 (50%) as compared to MLVs containing lower concentration of
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PIP2 (Figure 18). Also, the full length talin mutant (talin-3E mutant) showed significantly
reduced binding to MLVs containing higher concentration of PIP2 (50%) as compared to
wild type full length talin (figure 18,19). These findings support the hypothesis that
electrostatic repulsion between the negatively charged talin-R9 and membrane promotes
cytosolic retention of autoinhibited talin.
The active mutant of talin F2R9 (D1676R, E1770K, M319A) shows stronger binding
to membrane as compared to the wild type talin F2R9 (Figure 22,23). Thus weakening of
the talin F3/R9 autoinhibition substantially enhances the binding of talin to membrane by
promoting the “pulling” of positively charged surface on talin-H to membrane and “
pushing” away of negatively charged surface on talin-R from membrane. This finding
supports the hypothesis that enrichment of membrane with negatively charged PIP2
promotes membrane localization and activation of autoinhibited talin via a “pull-push”.
mechanism. However, approximately 60% of the total FL wild type talin pellets down
with MLVs enriched with higher percentage (50%) of PIP2 (figure 18,19) which suggests
the involvement of other cellular mechanisms in regulating activation of talin and its
localization from cytosol to membrane. Banno et al. (2012) have shown that an
interdomain interaction between Talin 466-787, a region of talin containing two vinculin
binding sites, and Talin F2F3 prevents localization of talin to membrane. RIAM (Rap1GTP interacting adaptor molecule) which binds to both a member of Ras subfamily, Rap1
and talin has been shown to be required for activation of integrin αІІbβ₃ in CHO cells
(Lee et al, 2009). Further investigation of the role of Rap1/RIAM in talin’s localization to
membrane and possibly it’s activation would be helpful in understanding the mechanism
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of talin mediated integrin activation. Also, the crystal structure of FL talin would be
valuable in understanding how binding to membrane and integrin is inhibited in FL talin.
Active mutant of F2R9 (D1676R, E1770K, M319A) showed increased binding to
integrin β₃ CT as compared to wild type talin F2R9 in NMR studies (Figure 24). Also FL
active triple mutant (T1767L, E1770K, M319A) showed increased integrin activation in
CHO cells (Figure 25). These results suggest that weakening of autoinhibition in talin
enhances talin mediated integrin activation and also the ability of talin to bind to
membrane. Perhaps localization of talin to membrane facilitates the interaction of talin
with integrin. In our NMR studies, Talin F2F3 showed significant perturbation of integrin
β₃ CT mainly in the membrane proximal region (figure 24). FL talin showed negligible
binding to β₃ CT. F2R9 showed weak interaction with β₃ CT and caused some
perturbation particularly in the membrane distal region of integrin β₃ CT (figure 24). This
finding suggests that an additional fragment of talin rod domain is involved in inhibiting
the interaction of FL talin with integrin.
Along with other proteins such as vinculin, talin forms a connection between
extracellular matix and actin cytoskeleton at sites of adhesion to substrate in activated
platelets and fibroblasts. The activation of these cells leads to redistribution talin to
membrane and polymerization of actin filaments and change in shape of cell (Beckerle et
al., 1989). Previous studies have indicated the presence actin binding sites on COOH
terminus, head domain and in rod domain (Hemmings et al., 1996). We used actin
cosedimentation assay in order to investigate the reported actin binding sites in talin. The
monomeric form of actin, Globular actin (G-actin) has been shown polymerize to
filamentous actin (F-actin) in physiological conditions such as 2mM MgCl2 and 100 mM
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KCl in presence of talin in invitro studies (Muguruma et al., 1990). Our study suggests
the presence of an actin binding site on F2F3, R1-R9 and R13-DD domain of talin, each
of which binds to F-actin (Figure 26). However, FL talin does not show additive binding
to F-actin due to the presence of three actin binding sites (figure 27). It rather shows
significantly reduced binding to F-actin as compared to F2R9, F2R10 and F2R12 which
suggests that the FL talin is not only conformationaly restricted to bind integrin but also
F-actin. The triple talin FL mutant (T1767L, E1770K M319A) also showed little binding
to F-actin (figure 27, 28). Thus the disruption of the autoinhibitory F3/R9 interface in
talin which masks the integrin binding site on F3 increased the binding of talin to integrin
but not to actin. These findings suggest that binding of talin to integrin and actin is
regulated by different conformational activation mechanisms. Further investigation of the
mechanisms which regulate binding of talin to actin will help us better understand the
role of talin in actin mediated changes in cell morphology and motility and focal adhesion
turnover.
In summary, we have defined a “pull-push” mechanism which promotes membrane
localization and activation of autoinhibited talin. Our results suggest that autoinhibited
talin remains in cytosol due to electrostatic repulsion between negatively charged surface
on R9 and plasma membrane. The enrichment of membrane with PIP2 promotes the
pulling of positively charged talin-H to membrane and pushing away of negatively
charged talin-R from membrane which in turn leads to localization of talin to membrane
and it’s activation. Consistent with previous studies our results suggest the presence of
three actin binding sites on talin. We found that full length talin adopts a conformation
which not only prevents the integrin binding but also the binding of talin to actin. Our
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studies suggest that the two binding events are regulated by different conformational
activation mechanisms.
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3.3

Elution Profiles of Proteins

Talin 206-1848 wild type

10.43 ml
150 KDa

Superdex 200

Talin 206-1848 D1676R, E1770K, M319A

10.3 ml
150 KDa

Superdex 200
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Talin 206-1973

10.6 ml
250 KDa

Superdex 200

Talin 206-2294
10.43 ml
250 KDa

Superdex 200

48

Talin 206-2541

13.2 ml
250 KDa

Superose 6

Talin full length (1-2541)

13 ml
250 KDa

Superose 6

49

Talin full length H1711E, T1812E, N1815E

12.9 ml
250
KD
a

Superose 6

Talin full length T1767L, M319A, E1770K
13.4 ml

250 KDa

Superose 6
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Biorad gel filtration standard (Superdex 200)
1.35 KDa

20.854ml
17 KDa

158 KDa

44 KDa

670 KDa
12.07 ml

17.12 ml

9.22 ml
14.97ml

Biorad gel filtration standard (Superose 6)

158 KDa

17 KDa

16.22 ml 19.06 ml
670 KDa

44 KDa
13.1 ml

18 ml

1.35 KDa
22.14 ml
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